ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 28

Evidence for Receptor Activator of NF-Kb (RANK)-Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis

William R. O'Brien1, Julia F. Charles2, Kelly Tsang1 and Antonios O. Aliprantis1, 1Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: bone remodeling, inflammatory arthritis and osteoclasts, RANK/RANKL pathway

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose: A gain-of-function mutation in the adaptor Src Homology 3 Binding Protein 2 (SH3BP2) causes Cherubism, a rare pediatric disease marked by aggressive bone remodeling in the mandible and maxilla.  Mice homozygous for the most common Cherubism mutation (Sh3bp2KI/KI) display TNFa-dependent osteopenia and inflammatory arthritis with peri-articular bone erosions. We sought to investigate whether bone-resorbing osteoclasts are key cellular mediators of the systemic bone loss and local inflammatory erosion observed in this model.  To this end, Sh3bp2KI/KI mice with an inducible mutation in Rank, encoding a master regulator of osteoclast differentiation, were generated.

Methods: We generated Sh3bp2KI/KI RANK-deficient mice using Mx1-Cre driven deletion of floxed Rank alleles after intra-peritoneal injection of poly-IC at 10-days of age (referred to as Sh3bp2KI/KI RankΔ/Δ).  Control mice, also treated with poly-IC, included Sh3bp2KI/KI Rankfl/fl without the Mx1-Cre transgene, Sh3bp2+/+Rankfl/fl and Sh3bp2+/+ RankΔ/Δ.  Bone mass, peri-articular erosions and synovitis were assessed by a combination of micro-computed tomography (mCT) and histology at 12 weeks of age.

Results: Neither Sh3bp2+/+Rankfl/fl nor Sh3bp2+/+ RankΔ/Δ displayed inflammatory arthritis or bone erosion. Sh3bp2+/+ RankΔ/Δ developed severe osteopetrosis, consistent with osteoclast-deficiency. As previously reported, Sh3bp2KI/KI sufficient for RANK (Sh3bp2KI/KI Rankfl/fl) developed osteopenia and inflammatory arthritis at the elbow joint with marked peri-articular erosions.  Depletion of osteoclasts by genetic deletion of Rank reversed the systemic osteopenia observed in Sh3bp2KI/KI mice but had no effect on synovitis at the elbow.  Unexpectantly, peri-articular erosions at the elbow joints were not ameliorated in Sh3bp2KI/KI RankΔ/Δ mice despite a significant reduction in tartrate-resistant acid phosphatase (TRAP) positive osteoclasts.

Conclusion:   Deletion of Rank inhibits osteoclastogenesis and reverses systemic osteopenia in Sh3bp2KI/KI mice.  In contrast, while the loss Rank reduces classic TRAP-positive osteoclasts at the inflamed elbow joints of Sh3bp2KI/KI mice, it does not reduce local bone erosion. These intriguing findings suggest an alternative pathway to bone erosion exists in the Sh3bp2KI/KI model of inflammatory arthritis that is independent of RANK.


Disclosure:

W. R. O’Brien,
None;

J. F. Charles,
None;

K. Tsang,
None;

A. O. Aliprantis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-for-receptor-activator-of-nf-kb-rank-independent-bone-erosion-in-the-cherubism-mouse-model-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology